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Abstract 
Background: Pulmonary neuroendocrine tumors (NET) form a heterogeneous group of rare diseases. In these 
tumors, paraneoplastic syndromes have been described to drive the course of the disease, among them acromegaly 
induced by paraneoplastic secretion of growth hormone-releasing hormone (GHRH).
Case presentation: We report the case of a 43 years old patient initially diagnosed with acromegaly accompanied 
by weight gain and acral enlargement. Subsequently, further diagnostic work-up identified a solitary pulmonary neu-
roendocrine tumor (NET). Laboratory tests revealed markedly increased growth hormone (GH) and insulin-like growth 
factor 1 (IGF-1) without GHRH elevation in the absence of pituitary pathologies confirming the paraneoplastic origin 
of clinical presentation with acromegaly. Curative surgery was performed leading to normalization of the elevated 
hormone levels and improvement of the clinical symptoms. Immunohistochemically, a typical carcinoid (TC) was seen 
with low proliferation index and abundant IGF-1 expression.
Conclusions: The association of acromegaly and pulmonary NET has only rarely been reported. We present an 
individual case of paraneoplastic GH- and IGF-1 secretion in a patient with pulmonary NET. Based on their rarity, the 
knowledge of paraneoplastic syndromes occurring in patients with pulmonary NET such as acromegaly due to para-
neoplastic GH- and IGF-1 secretion is mandatory to adequately diagnose and treat these patients.
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Background
Pulmonary neuroendocrine tumors (NET) represent 
rare malignancies with an incidence between 0.2 and 
2.0/100.000 inhabitants [1]. The incidence is increasing 
over the last decades which probably reflects increased 
awareness of this entity. The literature describes up to 
25 % of all neuroendocrine neoplasias (NEN) and approx-
imately 2 % of all lung tumors as pulmonary NET [2–4]. 
Only few pulmonary NET (5 %) are associated with mul-
tiple endocrine neoplasia type 1 (MEN-1) syndrome [5]. 
Pulmonary NET can be classified into typical carcinoids 
(TC) and atypical carcinoids (AC) based on clinico-
pathological features [4]. TC are 5–10 times more fre-
quently compared to AC. Up to 15 % of TC have already 
metastasized at time of presentation [6]. Histopathologi-
cal assessment comprises mitotic-index and necrosis to 
differ between both subtypes [7]. Moreover, pulmonary 
NET have been linked to hormone syndromes in up to 
30 % of the cases which include carcinoid-, cushing- and 
inappropriate antidiuretic hormone secretion syndrome 
as well as rarely acromegaly [4, 8]. Less than 1  % of all 
acromegaly cases are caused by non-pituitary tumors. In 
these cases, usually growth hormone (GH) is hyperse-
creted [9]. This report presents a patient with acromegaly 
due to rare paraneoplastic GH and IGF-1 secretion medi-
ated by a pulmonary NET.
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Case report
Three years before presenting at our ENETS center, when 
he was 43  years old, the patient was diagnosed with a 
WHO grade 1 subependymoma. This intracranial lesion 
was resected microsurgically in an external hospital. Fur-
ther pre-existing conditions were unknown. After sur-
gery the patient complained about dyspnea and cough. 
An X-ray examination at that time revealed a right-sided 
basal pneumonia, which was treated with antibiotics. 
However, during the following years, the patient suf-
fered from an abnormal feeling of satiety, weight gain of 
20 kg in 3 years and acral enlargement (Fig. 1). His shoe 
size increased from 44 to 46, the size of gloves from 9 to 
11. Furthermore, he developed pain in his ankles, knees 
as well as in his hips and femur. He noticed a protru-
sion of the jaw and a clipped speech due to macroglossia 
and sleeping apnea. Repeated contrast-enhanced imag-
ing studies were performed to rule out pathologies at 
the level of the pituitary gland. These examinations did 
not reveal any evidence of a pituitary adenoma. How-
ever, growth hormone (GH) and insulin-like growth fac-
tor 1 (IGF-1) levels were found to be massively elevated 
(Table  1). In contrast, growth hormone-releasing hor-
mone (GHRH) was not elevated. GH suppression testing 
showed clearly the presence of a clinically active acro-
megaly. A subsequent 68Gallium-DOTATOC PET-CT 
revealed a large tumor-atelectasis-complex in the right 
basal upper lobe with a compression of the middle and 
lower bronchus with somatostatin receptor positivity 
indicative for a well-differentiated neuroendocrine pul-
monary tumor (Fig.  2). Retrospectively, a tumor forma-
tion could be assumed when comparing X-ray images of 
2010 with actual PET-CT. Metastatic lesions were not 
detected by PET-CT indicating a localized disease stage. 
Subsequently, endobronchial ultrasound with transbron-
chial needle aspiration was performed. The tissue was 
analyzed immunohistochemically revealing an intense 
positive staining for synaptophysin, chromogranin A and 
CD 56 with a small amount of Ki-67 positive cells (Fig. 3). 
In contrast, TTF-1 was negative. Following interdisci-
plinary tumor board recommendation, the patient has 
been resected in curative intent and lobectomy was per-
formed. Afterwards, immunohistochemical evaluations 
presented a typical pulmonary carcinoid (Ki-67  <  2  %) 
with abundant IGF-1 expression as cause of the acromeg-
aly (Figs.  3 and 4). Postoperative blood tests confirmed 
the normalization of circulating GH and IGF-1 as mark-
ers of complete removal of the tumor (Table 1). Clinically, 
the patient improved dramatically. Analysis of the cod-
ing region of the MEN 1-gen (Exon 2–10; Chromosome 
11q13) and flanking intron regions did not reveal any 
aberration of the sequence or deletion/duplication of sin-
gle exons. Moreover, also the family history of the patient 
did not present the diagnosis of a neuroendocrine neo-
plasia. To date, the patient is recurrence-free and under 
follow-up.    
Discussion
Pulmonary neuroendocrine tumors
Up to 2  % of all lung cancers are pulmonary neuroen-
docrine tumors [2, 4, 10]. 25  % of all neuroendocrine 
tumors are located in the respiratory tract what makes 
them the most frequent extraintestinal site for NET 
[11]. The reported annual incidence of pulmonary NET 
equals about 1.35/100,000 [12]. These malignancies form 
a heterogeneous subset of neoplasias including typical 
(TC) and atypical carcinoid (AC) tumors, large cell neu-
roendocrine carcinoma (LCLC) and the most frequently 
occurring small cell lung cancer (SCLC) which is mostly 
considered as separate entity. Poorly differentiated neu-
roendocrine carcinomas display a highly distinct pheno-
type compared to pulmonary NET in terms of prevalence, 
biology and prognosis. The following discussion will 
focus on the typical and atypical carcinoid tumors, since 
poorly differentiated neuroendocrine carcinomas are 
characterized by a grossly different biological behavior 
and are associated with a poor prognosis. Pulmonary 
Fig. 1 Representative image of the patient’s hand (left side) before 
surgery compared to a hand of one of our doctors





GH in ng/ml <0.8 10.2 0.3
IGF-1 in µm/l 101–267 1294 261
CgA in U/l <18 164 31
HbA1c in  % <6 6.8 6.0
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Fig. 2 68Gallium-DOTATOC PET-CT before surgery revealed a large tumor mass located in the right lung with high somatostatin receptor expression. 
Isolated CT- and PET component (a left side and b) is presented as well as combined images (a right side). Metastatic spread was excluded as seen 
on the planar reconstruction (b right side)
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NET frequently develop in the bronchial system. There-
fore, they likely cause coughing, wheezing, hemoptysis 
and recurrent pneumonia [13]. If metastasized, typical 
have a considerably better prognosis compared to atypi-
cal NET (15 vs. 50  % risk of metastatic disease by first 
presentation). According to prior published series, 5- and 
10-year survival rates are 80 % for TC (both time points) 
and 50 and 35 % for AC stage [1, 14].
Paraneoplastic endocrine syndromes (ectopic hormone 
production)
Paraneoplastic endocrine syndromes (PES) are caused 
by tumors capable of producing a variety of function-
ally active peptides that imitate hormone function and 
lead to a metabolic disturbance [15]. Tumors derived 
from tissues that normally do not produce hormones 
lead to “ectopic” or “inappropriate” hormone production 
[16]. Neoplastic dedifferentiation can possibly activate 
repressed genes. That is the reason why this phenomenon 
most frequently arises in dedifferentiated tumors such as 
small cell lung cancer [17]. Commonly occurring PES are 
ACTH or CRH production leading to cushing syndrome, 
hypercalcemia caused by parathyroid hormone-related 
protein or syndrome of inappropriate secretion of anti-
diuretic hormone (SIADH).
Fig. 3 Neuroendocrine tumor with typical growth pattern. Tumor cells show intermediate cytological pleomorphy and a distinct ‘‘pepper and salt’’ 
chromatin of the nucleolus as well as details of the so called “Zellballen” or nesting pattern (a). Antibodies directed against chromogranin a show 
a strong staining pattern (b) while synaptophysin is intermediately expressed (c). Immunohiostochemical staining with antibodies against Ki-67 
indicate a low proliferation rate <2 % (d)
Fig. 4 Abundant cytoplasmic protein expression of IGF-1 in the 
resected tumor specimen as detected by immunohistochemistry
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In our case the patient presented with the rare paraneo-
plastic manifestation of acromegaly. Acromegaly repre-
sents a rare condition usually affecting middle-aged adults 
with a prevalence of 40–70 cases per million and an inci-
dence rate of 3–4 cases per million per year [18–21]. This 
disease mostly results from persistent hypersecretion of 
growth hormone (GH) leading to hepatic overproduction 
of insulin-like growth factor-1 (IGF-1). However, both 
hypersecretion of growth hormone-releasing hormone 
(GHRH) and growth hormone (GH) may lead to acro-
megaly. These hormones are produced by the pituitary 
gland or non-pituitary tumors rarely occur in association 
with familial syndromes. The vast majority of about 90 % 
of the patients with acromegaly have a benign pituitary 
adenoma with monoclonal GH secretion whereof 70  % 
are macroadenomas (>1 cm) at diagnosis [22, 23]. Ectopic 
secretion of GH has only been described in single cases 
[24, 25]. Non-pituitary tumors such as small-cell lung 
cancer, adrenal adenoma, medullary thyroid carcinoma 
or pheochromocytoma or pancreatic neuroendocrine 
tumors can lead to acromegaly by production of growth 
hormone–releasing hormone (GHRH) [26]. Peripheral 
production of GHRH causes hyperstimulation of soma-
totroph cells with subsequently increased GH secretion 
and hepatic IGF-1 release. Ectopic acromegaly represents 
less than 1 % of the reported cases of acromegaly [27]. The 
most common signs are—as the name suggests—acral and 
soft tissue overgrowth and the typical coarse facies. Acral 
enlargement is typically noticed by tightness of rings or an 
increasing shoe size. As physical changes occur gradually 
clinical diagnosis is often delayed. If acromegaly is sus-
pected IGF-1 measurement and a GH suppression test 
will be performed. Imaging helps to pinpoint the loca-
tion and the size of a suspected tumor. Cardiac and res-
piratory disorders along with arthropathy rank amongst 
the most frequent systemic complication that lead to 
increased morbidity and mortality [28, 29]. Patients ben-
efit extensively from controlling GH and IGF-1 hyperse-
cretion either surgically or by pharmacotherapy [30]. This 
can effectively be achieved by somatostatin. Long act-
ing somatostatin analogs may control ectopic hormonal 
secretion syndrome, and restrict tumor growth [31].
Single cases of neuroendocrine tumors causing acro-
megaly have been described with tumors deriving from 
duodenum [32], liver [33] and from the pancreas in the 
context of multiple endocrine neoplasia type 1 [9, 34, 35]. 
In addition, acromegaly due to GHRH hypersecretion in 
carcinoid tumors is the most common cause [27, 36, 37], 
whereas paraneoplastic GH secretion is extremely rare in 
NET [24].
In summary, the case presented here is an extremely 
rare example of a sporadic pulmonary NET associated 
with GH and IGF-1 but not GHRH secretion, thereby 
inducing a clinically florid acromegaly. Thus, mostly 
inapparent pulmonary NET induce relevant symptoms 
which should accurately be clarified.
Methods
We retrospectively analyzed a patient with a pulmonary 
NET treated and followed-up in our institution since 
2013. This case presentation was conducted in accord-
ance with the Declaration of Helsinki. Tumor tissue was 
explored immunohistochemically concerning expression 
of chromogranin A, synaptophysin and Ki-67. Analyses 
were performed according to a standardized protocol 
using Leica-Bond-Max-Autostainer and the antibodies in 
the following dilutions: Chromogranin: Dako 1:400; Syn-
aptophysin: Dako 1:400; Ki-67: Dako 1:1000. For IGF-1 we 
used the ABCM ab 40,657 in the following dilution: 1:400.
The CARE guidelines were followed in accordance with 
the journal policies.
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